Official announcements
Search narrowed by
messages in brief
|
28/05/2015
Situation in Austria As of June 25, 2015, remote sales of over-the-counter pharmaceutical specialties approved in Austria will be made possible. Interested domestic, public pharmacies can register for this with immediate effect. more information: http://www.basg.gv.at/inspektionen/versandapotheken/ Requirements In order to be authorized to engage…
Safety warnings
|
messages in brief
|
12/05/2015
Measures at EU level The European Medicines Agency (EMA) would like to increase the acceptance of participation of children and adolescents in clinical trials. To this end, a questionnaire has been designed that is aimed at children and adolescents between the ages of 10 and 18. It contains 11 questions and is divided into two parts. The first part…
Safety warnings
|
messages in brief
|
28/04/2015
The Federal Office informs about recommendations of the European Medicines Agency EMA regarding a restriction of the use of new hepatitis C drugs together with amiodarone. Measures at EU level The European Medicines Agency (EMA) has confirmed that there is an increased risk of severe bradycardia (abnormally slowed heartbeat) or cardiac conduction…
Safety warnings
|
messages in brief
|
23/01/2015
Measures at EU level An inspection at the research service provider GVK Biosciences in Hyderabad (India) revealed serious deficiencies in the bioequivalence studies conducted there, which serve as the basis for the approval of generic drugs. Across Europe, more than 1,000 medicines were affected. The European Medicines Agency (EMA) has completed…
messages in brief
|
15/01/2015
Measures at EU level The EU Commission has released the emergency contraceptive "ellaOne" (active ingredient: Ulipristal) from prescription-only status. In doing so, the Brussels-based authority has followed the recommendation of the European Medicines Agency (EMA), which had come out in favor of a release in November. This decision applies to all…
Safety warnings
|
messages in brief
|
04/01/2015
Isotretinoin is a highly effective vitamin A analogue that has been used since the early 1980s to treat severe, therapy-resistant forms of acne. When isotretinoin is taken during pregnancy, the risk of severe congenital malformations or spontaneous abortion is comparable to that after exposure to thalidomide. Isotretinoin is therefore absolutely…
Safety warnings
|
messages in brief
|
12/12/2014
An inspection by the French Medicines Agency (ANSM) of the research service provider GVK Biosciences in Hyderabad (India) has revealed serious deficiencies in the conduct of bioequivalence studies for the approval of generic drugs. There is suspicion that relevant study parameters were deliberately falsified, which is a massive violation of Good…
Safety warnings
|
messages in brief
|
06/12/2014
An inspection by the French Medicines Agency (ANSM) of the research service provider GVK Biosciences in Hyderabad (India) has revealed serious deficiencies in the conduct of bioequivalence studies for the approval of generic drugs. There is suspicion that relevant study parameters were deliberately falsified, which is a massive violation of Good…
Safety warnings
|
messages in brief
|
28/11/2014
Austria has been informed by the Italian Medicines Agency (AIFA) of a precautionary suspension of two batches (142701 and 143301) of the influenza vaccine Fluad. The reason for the suspension is the occurrence of serious adverse events that have been reported in a temporal relationship with the vaccination. Currently, there is no confirmed causal…
Safety warnings
|
messages in brief
|
17/10/2014
The Federal Office provides information on recommendations of the Committee for Risk Assessment and Pharmacovigilance (PRAC) within the framework of the European risk assessment procedure according to Article 31 of Directive 2001/83/EC regarding the use of valproate during pregnancy. All these recommendations are to a large extent already currently…